Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer

Roya Dolatkhah ¹ , Saeed Dastgiri ² , Amir Taher Eftekhar Sadat ³, Faris Farassati ⁴, Marzieh Nezamdoust ⁵, Mohammad Hossein Somi ³ *

Cited by CrossRef: 4

1- Day N, Kearsey C, Sutton P. Neoadjuvant treatment of advanced colonic cancer: a paradigm shift?. 2022;109(10):895 [Crossref]

2- Wang Q, Shen K, Fei B, Wei M, Xie Z. Nomogram for predicting occurrence and prognosis of liver metastasis in elderly colorectal cancer patients: a population-based study. Front Oncol. 2024;13 [Crossref]

3- Chan A, Mason J, Baltatzis M, Siriwardena A, Sheen A, O’Reilly D, Jamdar S, Deshpand R, de Liguori Carino N, Satyadas T, Mullamitha S, Braun M, Alam N, Hassan J, Wilson G, Rajashankar R, Jegatheeswaran S, McMahon R, Sethi R, Hill J, Smith D, Smart C, Khan A, Kurrimboccus M, Epstein J, Reid F, Siddiqui K, Aswatha R, Paraoan M. Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC). Ann Surg Oncol. 2022;29(3):1939 [Crossref]

4- Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard‐Tessier A, Turpin A, Palmieri L, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Intl Journal of Cancer. 2022;151(11):1978 [Crossref]

5- Jang J, Kim D, Kim N. Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors. IJMS. 2023;24(9):8457 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons